Journal Club: The COVID-19 Pandemic and the Use of MS Disease Modifying Therapies

Release Date: July 8, 2020

Valid for Credit Through: July 31, 2021


Advanced Perspectives in MS: A Virtual Journal Club Series for the Multiple Sclerosis Clinician


The COVID-19 Pandemic and the Use of MS Disease Modifying Therapies


This activity has been designed to meet the educational needs of physicians, PAs, nursing professionals, pharmacists, and other members of the healthcare team involved in the management of patients with MS.


Upon completing this activity, participants should be better able to:

Identify the latest research and clinical information available describing use of disease modifying therapies in patients with MS during the COVID-19 pandemic.


John F. Kramer, PA-C
STMP Neurology
Nashville, TN

Bryan D. Walker, MHS, PA-C, MSCS
Duke University Medical Center
Durham, NC


This activity is supported by educational grants from Celgene Corporation, EMD Serono, Genentech, and Mallinckrodt Pharmaceuticals.


In support of improving patient care, the Consortium of Multiple Sclerosis Centers (CMSC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The CMSC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers designates this enduring material for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The Consortium of Multiple Sclerosis Centers designates this enduring material for 1.0 contact hours of continuing education (1.0 in the area of pharmacology) for nurses.

This knowledge-based activity (UAN # JA4008165-0000-20-033-H01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.

All other healthcare professionals completing this activity will be issued a certificate of participation.


In accordance with the ACCME Standards for Commercial Support, CMSC requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

The program faculty reported the following relevant financial relationships that they have with commercial interests:

John F. Kramer, PA-C (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, and Novartis Pharmaceuticals; Speakers Bureau: Alexion, Biogen, EMD Serono, and Genentech.

Bryan D. Walker, MHS, PA-C, MSCS (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, Novartis, and Sanofi-Genzyme; Speakers Bureau: Biogen.

The planners, reviewers, editors, staff, or other members at CMSC who are in a position to control content have declared that they have no relevant financial relationships.

CMSC requires faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and the commercial supporters assume no liability for the information herein.


Multiple Sclerosis and Related Disorders 39 (2020) 102073

The COVID-19 pandemic and the use of MS disease-modifying therapies

Gavin Giovannonia,*, Chris Hawkesa, Jeannette Lechner-Scottb, Michael Levyc, Emmanuelle Waubantd, Julian Golda,e

a Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK

b School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia

c NMO Clinic and Research Laboratory, Division of Neuroimmunology & Neuroinfectious Disease, Massachusetts General Hospital, Boston, USA

d Department of Neurology, UC San Francisco, San Francisco, California, USA

e The Albion Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre – including this research content – immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.


To successfully complete this live activity, the participant must review the accreditation information, including learning objectives and faculty disclosures, view the webinar, and complete the evaluation.

  1. To complete the evaluation and claim credit, please click on the To Claim Credit button below or go to:
  2. Log in with your user name and password*, or create a new account.
  3. Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.

*If you do forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.

This activity is best viewed using the most up to date version of Google Chrome, FireFox, Safari, or Microsoft Edge.

There is no fee to participate in this activity.


To view the CMSC Privacy Policy, visit our website at


If you have any questions about this activity, please contact the CMSC at [email protected] or 201-487-1050, ext. 102.

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts